Company Overview and News

0
FinMin seeks more time for PSBs to meet MPS norm

42m freepressjournal.in
New Delhi : The finance ministry may approach markets regulator Sebi to seek relaxation on the minimum 25 per cent public shareholding norm for some state banks (PSBs).
INDIANB IOB 500116 UDBKL IDBI UBLS 532418 532814 532505 CNRYY 532388 SYNDIBANK 532276 532121 532483 UBLA UCOBANK CANBK DENABANK ANDHRABANK

0
Canara Bank - Updates

2018-07-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532483 CANBK CNRYY

1
D-Street Buzz: Bulls roar as RIL jumps 4%, hits record high; GMR Infra zooms 8%, PSU banks rally

2018-07-12 moneycontrol
Bulls have taken complete control of Dalal Street with the Indian benchmark indices up over 1 percent. The Nifty has jumped 127 points and is trading at 11,069 mark while the Sensex is trading higher by 423 points at 36,689, reaching a new record high.
IOC 500408 500325 HCTHY 532483 532480 500696 532281 BJJQY RLNIY SBAZ ALBK YYBKY 530965 530005 CNRYY BAJFINANCE HCLTECH 500180 KOTAKBANK TCS CANBK RELIANCE HINDUNILVR 533155 532856 TTNQY JUBLFOOD 532540 532187 532461 RIGD JBLWY HDFCBANK INDIACEM 500034 YESBANK UBNC INDUSINDBK KMBKY IBN 532648 ICICIBANK PNJZY HDB 532174 TATAELXSI PNB 500247 TIMETECHNO

0
Can Fin Homes board to consider debenture issue

2018-07-11 thehindubusinessline
Can Fin Homes’ board will meet next week to consider raising up to Rs 6,000 crore through issuance of debentures on a private placement basis. Can Fin Homes is a subsidiary of state-owned Canara Bank.
532483 CANFINHOME 511196 CANBK CNRYY

0
State banks plan to raise Rs 50k-cr equity capital this fiscal

2018-07-09 freepressjournal.in
New Delhi : Public sector banks are planning to tap the markets to raise more than Rs 50,000 crore this fiscal to shore up their capital base for business growth and meeting regulatory global risk norms.
532483 CANBK CNRYY

0
PNB#39;s big wilful defaulters#39; dues fall to Rs 15,354 crore in June

2018-07-08 moneycontrol
Dues from big wilful defaulters of Punjab National Bank fell by 0.87 per cent to Rs 15,354.52 crore on June 30 compared to previous month, the bank data has showed.
PNJZY 532461 532483 PNB CANBK CNRYY

0
PSU banks plan to raise over Rs 50k crore equity capital in FY19

2018-07-08 moneycontrol
Public sector banks are planning to tap the markets to raise more than Rs 50,000 crore this fiscal to shore up their capital base for business growth and meeting regulatory global risk norms.
ALBK 532505 CNRYY 532179 SYNDIBANK 532276 532121 532483 CRPKY 532480 CORPBANK UCOBANK CANBK DENABANK

0
Lenders favour Srei’s bid for Deccan Chronicle

2018-07-06 freepressjournal.in
Hyderabad : A majority in the committee of creditors for Deccan Chronicle Holdings favour Srei Infrastructure Finance’s bids to take over the company, sources said.
SRI SREINFRA IDBI 532418 532215 532662 532483 AXISBANK SIFLY 523756 500116 AXB KMBKY IBN HTMEDIA SRIA CNRYY AXBKY AXBA ICICIBANK 532174 KOTAKBANK 500247 CANBK ANDHRABANK

0
Canara Bank - Statement of deviation(s) or variation(s) under Reg. 32

2018-07-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532483 CANBK CNRYY

0
Canara Bank - Updates

2018-07-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532483 CANBK CNRYY

1
An evening walk down Dalal Street: Sensex rallies over 100 points; Nifty ends around 10,700

2018-07-03 moneycontrol
The S&P BSE Sensex recovered sharply from opening lows and closed with gains of over 100 points on Tuesday while the Nifty50 witnessed a touch and go moment with 10,700 levels.
500116 TGBA 500800 TATACOFFEE TTAZF IDBI ALBK 532967 KIRIINDUS ABAN CNRYY TTAEY 532301 TGBL 532483 HDB 500180 532480 HDFCBANK CANBK 523204 TATAGLOBAL

1
Canara Bank - Updates

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532483 CANBK CNRYY

5
Bank Boards Bureau recommends 15 names for the post of MD in PSU banks

2018-06-30 livemint
Mumbai: The Bank Boards Bureau has recommended the names of 15 officials for the posts of managing director and chief executive officers in several public sector banks.
INDIANB UBNC 500116 UDBKL IDBI ALBK UBLS 532814 CNRYY 532179 SYNDIBANK 532276 532483 CRPKY UBLA 532480 CORPBANK CANBK SBAZ

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...